What is the current valuation of the US Nucleic Acid Based Therapeutics Market?

The market valuation was 131.19 USD Million in 2024. Read More

What is the projected market valuation for the US Nucleic Acid Based Therapeutics Market in 2035?

The projected valuation for 2035 is 196.45 USD Million. Read More

What is the expected CAGR for the US Nucleic Acid Based Therapeutics Market during the forecast period 2025 - 2035?

The expected CAGR during this period is 3.74%. Read More

Which companies are considered key players in the US Nucleic Acid Based Therapeutics Market?

Key players include Amgen Inc, Gilead Sciences Inc, Regeneron Pharmaceuticals Inc, and others. Read More

What are the main applications of nucleic acid-based therapeutics in the US market?

Main applications include Gene Therapy, RNA Interference, Antisense Oligonucleotides, CRISPR Technology, and Vaccines. Read More

What is the valuation range for Gene Therapy in the US Nucleic Acid Based Therapeutics Market?

The valuation range for Gene Therapy is between 40.0 and 60.0 USD Million. Read More

How do DNA Based Therapeutics compare to RNA Based Therapeutics in terms of market valuation?

DNA Based Therapeutics have a valuation range of 30.0 to 45.0 USD Million, while RNA Based Therapeutics range from 40.0 to 60.0 USD Million. Read More

What is the market valuation for pharmaceutical companies involved in nucleic acid-based therapeutics?

Pharmaceutical companies have a valuation range of 50.0 to 75.0 USD Million. Read More

What role do research institutions play in the US Nucleic Acid Based Therapeutics Market?

Research institutions account for a valuation range of 30.0 to 45.0 USD Million. Read More

What is the projected growth trend for oligonucleotide therapeutics in the US market?

Oligonucleotide Therapeutics are projected to have a valuation range of 35.0 to 50.0 USD Million. Read More

US Nucleic Acid Therapeutics Market

ID: MRFR/HC/11123-HCR

128 Pages

Vikita Thakur

Last Updated: April 06, 2026

United States Nucleic Acid Therapeutics Market Research Report: Size, Share, Trend Analysis By Products (Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others), By Applications (Monogenetic Disorders and Multi-genetic Disorders), By End Users (Hospitals and Clinics and Academic and Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Gene Therapy
  2. 4.1.2 RNA Interference
  3. 4.1.3 Antisense Oligonucleotides
  4. 4.1.4 CRISPR Technology
  5. 4.1.5 Vaccines
2. 4.2 Healthcare, BY Type (USD Million)
  1. 4.2.1 DNA Based Therapeutics
  2. 4.2.2 RNA Based Therapeutics
  3. 4.2.3 Oligonucleotide Therapeutics
  4. 4.2.4 Gene Editing Technologies
3. 4.3 Healthcare, BY End Use (USD Million)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Research Institutions
  3. 4.3.3 Biotechnology Firms
  4. 4.3.4 Academic Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Gilead Sciences Inc (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Regeneron Pharmaceuticals Inc (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Vertex Pharmaceuticals Inc (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Ionis Pharmaceuticals Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sarepta Therapeutics Inc (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Alnylam Pharmaceuticals Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis AG (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY END USE
5. 6.5 KEY BUYING CRITERIA OF HEALTHCARE
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF HEALTHCARE
8. 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
9. 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
11. 6.11 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
13. 6.13 HEALTHCARE, BY TYPE, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
  2. 7.2.2 BY TYPE, 2026-2035 (USD Million)
  3. 7.2.3 BY END USE, 2026-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US US Nucleic Acid Therapeutics Market Segmentation

US Nucleic Acid Therapeutics Market By Application (USD Million, 2026-2035)

Gene Therapy
RNA Interference
Antisense Oligonucleotides
CRISPR Technology
Vaccines

US Nucleic Acid Therapeutics Market By Type (USD Million, 2026-2035)

DNA Based Therapeutics
RNA Based Therapeutics
Oligonucleotide Therapeutics
Gene Editing Technologies

US Nucleic Acid Therapeutics Market By End Use (USD Million, 2026-2035)

Pharmaceutical Companies
Research Institutions
Biotechnology Firms
Academic Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”